Boston-based NeuroBo Pharmaceuticals, Inc. is leading the charge in developing and commercializing multimodal disease-modifying therapies for a range of diseases. With a focus on viral, neuropathic, and neurodegenerative illnesses, the clinical-stage biotechnology company has a pipeline of promising treatments. Among these are ANA001, an oral niclosamide formulation for moderate COVID-19 treatment, and NB-01, designed to tackle painful diabetic neuropathy. Additionally, NeuroBo's NB-02 targets cognitive impairment symptoms and modifies the progression of neurodegenerative diseases associated with the malfunction of tau protein. Moreover, Gemcabene, which the company is developing for various indications, including in combination with ANA001 for COVID-19 patients.
NeuroBo Pharmaceuticals, Inc.'s ticker is NRBO
The company's shares trade on the NASDAQ stock exchange
They are based in Boston, Massachusetts
There are 11-50 employees working at NeuroBo Pharmaceuticals, Inc.
It is https://www.neurobopharma.com/
NeuroBo Pharmaceuticals, Inc. is in the Healthcare sector
NeuroBo Pharmaceuticals, Inc. is in the Biotechnology industry
The following five companies are NeuroBo Pharmaceuticals, Inc.'s industry peers: